NEUROSCIENTIFIC BIOPHARMACEUTIC ORD
NeuroScientific Biopharmaceuticals Investigates Use of Stem Cell Technology on Chronic Diseases
NeuroScientific Biopharmaceuticals (ASX: NSB) is investigating the use of its newly-acquired StemSmart stem cell technology for complex indications including refractory Crohn’s disease and steroid-refractory GVHD (graft-versus-host disease). The company recently finalised the acquisition of Isopogen WA, which developed the patented technology for the manufacture of mesenchymal stromal cells (MSC), which are derived from adult human […]
NeuroScientific Biopharmaceuticals acquires Isopogen to advance stem cell therapy for neurodegenerative disorders
NeuroScientific Biopharmaceuticals (ASX: NSB) has announced it will acquire private company Isopogen WA and its StemSmart patented stem cell technology for the manufacture of mesenchymal stromal cells (MSC). The company will incorporate the cellular technology into a special access program involving the use of allogeneic bone marrow-derived MSC to treat neurodegenerative conditions where sustained healing […]
NeuroScientific hails potential breakthrough after early EmtinB study results
NeuroScientific Biopharmaceuticals (ASX: NSB) has published positive preliminary results from a pre-clinical study of its lead compound EmtinB in treating multiple sclerosis (MS). The full report is set to be published by the end of this month, although according to the company’s chief executive officer Matthew Liddelow, the early results already indicate a “potential breakthrough” […]
NeuroScientific’s EmtinB drug achieves positive results in pre-clinical MS research
NeuroScientific Biopharmaceuticals (ASX: NSB) has achieved positive results in pre-clinical studies using its lead drug candidate EmtinB to treat multiple sclerosis models. Independent research organisation Neuron Experts undertook the study to evaluate EmtimB as a potential therapeutic benefit for MS. MS is one of the most common immune-mediated neurodegenerative conditions with onset ranging between 20 […]
